An up­start in the poly­clon­al an­ti­body biz just lined up $50M for its plan to dis­rupt a multi­bil­lion-dol­lar busi­ness

The multi­bil­lion-dol­lar busi­ness for im­muno­glo­bin prod­ucts is dom­i­nat­ed by three key play­ers: CSL, Shire and Gri­fols. And one of them re­cent­ly in­vest­ed $50 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.